Theravance Biopharma, Inc.

NASDAQ:TBPH

Biotechnology

Healthcare
$17.03 -0.42%

-$0.07 today

Market cap
$882.64M
Beta
0.18
P/E (TTM)
7.4
EPS (TTM)
$2.23
52W Low $10.44High $21.03

Volume 10.02M

Average 0.43M

TBPH EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Theravance Biopharma, Inc.NASDAQ: TBPH

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$5.03M, compared with -$13.08M a year earlier. Trailing-twelve-month EBITDA was $142.5M.

Context

  • EBITDA amounted to 127.7% of revenue in FY2025, up 68.0 pp from a year earlier.
  • EBITDA increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether next quarter's EBITDA reaches the consensus estimate of $6.69M, a -91.0% change from the same quarter last year.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$5.03M-106.7% QoQ
Last fiscal yearDec 2025
$137.22M+456.9% YoY
LTMMar 2026
$142.5M+440.4% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+61.5%-91.0%-152.5 pp
1 year+456.9%——
3-year CAGR—-20.4%—
5-year CAGR-2.0%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
137.22M USD
Year-over-year change
+456.9%

EBITDA vs competitors

How TBPH compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +440.4% is the highest of 9, against a peer median of -34.7%.
  • EBITDA amounts to 129.8% of revenue for TBPH, versus a peer median of 287.6%.
TBPH Competitors
EBITDA for TBPH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TBPHTheravance Biopharma, Inc.LTM Mar 2026$142.5M USD+440.4%—129.8%
GERNGeron CorporationLTM Mar 2026-$36.95M USD+67.7%—18.8%
VALNValneva SELTM Mar 2026-€90.14M EUR-119.6%—57.7%
LENZLENZ Therapeutics, Inc.LTM Mar 2026-$108.13M USD-126.9%—515.2%
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026-$123.54M USD-796.7%—287.6%
TYRATyra Biosciences, Inc.LTM Mar 2026-$130.56M USD-36.2%——
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026-$145.24M USD-14.0%——
REPLReplimune Group, Inc.LTM Dec 2025-$311.38M USD-33.2%——
VIRVir Biotechnology, Inc.LTM Mar 2026-$438.52M USD+24.4%—669.6%
Peer median (excluding TBPH) —-34.7%—287.6%

Competitors are the stored peer set for TBPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue55.31M51.35M57.42M64.38M107.46M
Cost of Revenue193.66M63.39M40.62M37.64M5.52M
Gross Profit(138.35M)(12.05M)16.8M26.74M101.95M
Gross Margin-250.1%-23.5%29.3%41.5%94.9%
Research & Development201.55M70.07M46.34M38.05M37.41M
Selling, General & Admin99.3M67.07M70.45M69.17M73.65M
Operating Expenses119.44M79.91M72.84M73.69M115.2M
Depreciation & Amortization4.81M3.04M2M3.62M5.52M
EBITDA(232.83M)(76.08M)(51.65M)(38.45M)137.22M
EBITDA Margin-420.9%-148.2%-89.9%-59.7%127.7%
Operating Income(257.78M)(91.96M)(56.04M)(46.95M)(13.25M)
Operating Margin-466.1%-179.1%-97.6%-72.9%-12.3%
Interest Income1.11M8.55M9.12M4.88M0
Interest Expense8.55M6.37M2.35M2.55M2.46M
Other Income / Expenses(7.44M)(858K)6.77M2.34M142.49M
Income Before Tax(265.22M)(92.82M)(49.27M)(44.61M)129.25M
Pre-Tax Margin-479.5%-180.8%-85.8%-69.3%120.3%
Income Tax Expense(151K)9K5.92M11.8M23.35M
Net Income(199.43M)872.13M(55.19M)(56.42M)105.9M
Net Margin-360.6%1698.5%-96.1%-87.6%98.5%
EPS (Basic)(2.87)(1.26)(1.00)(1.15)2.10
EPS (Diluted)(2.87)(1.26)(1.00)(1.15)2.06
Weighted Avg Shares69.46M73.59M55.3M48.85M50.32M
Weighted Avg Shares (Diluted)69.46M73.59M55.3M48.85M51.51M

Theravance Biopharma, Inc.

NASDAQ:TBPH

Intrinsic Alpha fair value

Locked

Current Price

$17.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.